No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NVAX250110C5500
- 0.00
- 0.000.00%
15min DelayClose Jan 7 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.50Strike Price0.00Turnover949.03%IV-49.17%PremiumJan 10, 2025Expiry Date5.32Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8890Delta0.0206Gamma1.78Leverage Ratio-0.3103Theta0.0003Rho1.58Eff Leverage0.0018Vega
Intraday
- 5D
- Daily
No Data
News
Options Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Why Novavax (NVAX) Stock Is Rising
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.